Gilead grants EVA Pharma a non-exclusive royalty-free voluntary licence to manufacture and supply generic lenacapavir

The licensee is an Egyptian manufacturer taking manufacturing rights to a patented HIV medicine; the African nexus is party-domicile and manufacturing-location based.


Coverage: The Meridian legal market record (editorial).

The licensee is an Egyptian manufacturer taking manufacturing rights to a patented HIV medicine; the African nexus is party-domicile and manufacturing-location based.

Record ID TX-AFR-2024-0001
Record type Commercial IP transaction
Transaction type Patent licence, Non-exclusive licence, Technology transfer, In-licensing
IP rights patent, know-how, regulatory data
Status Signed
Qualifying date 2024-12 (month precision)
Sector Life sciences · Pharmaceuticals – HIV
African markets Egypt
Licensed territory The release describes a voluntary licence to manufacture and supply generic lenacapavir; the territory list is not reproduced in the material reviewed.
Disclosed value Not disclosed in the sources reviewed.
Evidence Primary source, single · 1 source(s)
Last verified 2026-10-25

Parties

  • EVA Pharma (Egypt): licensee, manufacturer
  • Gilead Sciences (United States): licensor

Key terms

  • Interest: non-exclusive licence; Exclusivity: non-exclusive; Territorial scope: Not stated in material reviewed
  • Financial terms as reported: “non-exclusive, royalty-free voluntary licensing agreement”

Sources

  1. EVA Pharma announces non-exclusive, royalty-free voluntary licensing agreement with Gilead for generic lenacapavir, EVA Pharma (via APO Group Africa Newsroom), 2024-12-17

Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.